Table 2 Syntenin expression in relation to clinical parameters and pathological characteristics
From: Syntenin overexpression in human lung cancer tissue and serum is associated with poor prognosis
Variable | Number of sample | Syntenin | P | |
|---|---|---|---|---|
high (%) low (%) | ||||
Tumor size (cm) | ||||
  ≤ 3 | 70 | 24 (34.3) | 46 (65.7) | 0.002 |
 >3 | 121 | 69 (57.0) | 52 (43.0) |  |
TNM stage | ||||
 I + II | 80 | 31 (38.8) | 49 (61.2) | 0.020 |
 III + IV | 111 | 62 (55.9) | 49 (44.1) |  |
Distant metastasis | ||||
 Negative | 133 | 58 (43.6) | 75 (56.4) | 0.033 |
 Positive | 58 | 35 (60.3) | 23 (39.7) |  |
Lymphnode | ||||
 metastasis | ||||
  Negative | 91 | 38 (41.8) | 53 (58.2) | 0.067 |
  Positive | 100 | 55 (55.0) | 45 (45.0) |  |
Sex | ||||
 Men | 140 | 68 (48.6) | 72 (51.4) | 0.956 |
 Women | 51 | 25 (49.0) | 26 (51.0) |  |
Age (years) | ||||
  ≤ 60 | 84 | 39 (46.4) | 45 (53.6) | 0.579 |
 >60 | 107 | 54 (50.5) | 53 (49.5) |  |
Performance status | Â | Â | Â | 0.961 |
  ≤ 2 | 162 | 79 (50.1) | 83 (53.5) |  |
  > 2 | 29 | 14 (48.3) | 15 (51.7) |  |